(Q62041711)
Statements
A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL) (English)
0 references
28 November 2018
0 references
November 2020
0 references
264
0 references
16 year
0 references